Abstract: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.

Abstract: This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1+ multipotent cells. The method of the invention is useful in the treatment of spinal conditions characterized by degeneration of the invertebral disc.

Abstract: The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.

Abstract: This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1? multipotent cells. The method of the invention is useful in the treatment of spinal conditions characterized by degeneration of the invertebral disc.

Abstract: This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.

Abstract: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.

Abstract: This application provides methods for treating a human subject suffering from a bone fracture by administering to the subject a population of cells enriched from STRO-1+ multipotential cells and/or multipotential progeny of such cells.

Abstract: The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.

Abstract: The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.

Abstract: The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.

Abstract: The present invention relates to methods of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) and/or progeny derived therefrom in vitro or in vivo comprising exposing the MPC or progeny to SDF-1 or analog thereof. The invention also relates to compositions comprising isolated MPCs or progeny derived therefrom and SDF-1 or analogues thereof. The present invention also relates to using such methods and compositions for ex vivo or in vivo bone formation in mammals.

Abstract: This application provides methods for treating a human subject suffering from a bone fracture by administering to the subject a population of cells enriched from STRO-1+ multipotential cells and/or multipotential progeny of such cells.

Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1bri. The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.